-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] On April 15, Lianhuan Pharmaceutical released a good news.
The company's doxycycline hydrochloride tablets passed the consistency evaluation, and the company also became the first company to pass the evaluation of this variety
.
Up to now, Lianhuan Pharmaceutical has invested about 10.
5647 million yuan in research and development expenses for the consistency evaluation of the drug
.
Public information shows that doxycycline hydrochloride is a tetracycline antibiotic, a broad-spectrum bacteriostatic agent, mainly used for upper respiratory tract infections, tonsillitis, biliary tract infections, and lymphadenitis caused by sensitive gram-positive cocci and gram-negative bacilli.
, cellulitis, senile chronic bronchitis, etc.
, also used for typhus, scrub typhus, mycoplasma pneumonia and so on
.
In addition, it can also be used to treat cholera and to prevent falciparum malaria and leptospirosis infection
.
In China, the approved dosage forms of doxycycline hydrochloride include enteric-coated capsules, dispersible tablets, capsules, capsules, tablets, injections, etc.
, of which capsules occupy half of the country, followed by tablets and injections, accounting for 24.
06%, 22.
24%
.
Statistics from Minet.
com show that in 2019, the sales of full doxycycline dosage forms in the three major terminal public hospitals of cities, counties and townships in China were about 200 million yuan
.
There are many manufacturers of this variety.
According to incomplete data, doxycycline hydrochloride tablets alone have 61 companies in the domestic market, including Lianhuan Pharmaceutical, Dongfeng Pharmaceutical, Huanan Pharmaceutical, Daxin Pharmaceutical, Changzhou Pharmaceutical Factory, etc.
, a total of 77 production approvals
.
In terms of consistency evaluation, Lienhuan Pharmaceutical is the first company to pass the consistency evaluation of this variety
.
In addition, Teyi Pharmaceutical has also submitted a supplementary application for consistency evaluation
.
In recent years, policies such as centralized procurement and consistency evaluation have been successively introduced, which have a great impact on the market expansion of pharmaceutical products and profit growth
.
It is understood that in recent years, Lianhuan Pharmaceutical has adhered to the strategy of "innovating enterprises with science and technology and strengthening enterprises with science and technology", and has continuously strengthened related work such as the research and development of innovative drugs and the consistency evaluation of generic drugs.
Dr.
Ming has set up the company's doctoral workstation, continued to increase R&D investment and established an efficient R&D incentive mechanism.
Lihuan Pharmaceutical is making every effort to build a drug R&D highland, and the company has presented a good scientific and technological innovation atmosphere in which everyone pays attention to R&D and makes contributions
.
At the end of October 2021, the company received the "Approval Notice of Supplementary Drug Application" for ebastine tablets approved and issued by NMPA, and the company's ebastine tablets passed the consistency evaluation of generic drugs
.
Ebastine is a long-acting, highly selective histamine H1 receptor blocker indicated for allergic rhinitis with or without allergic conjunctivitis
.
In the first three quarters of 2021, Lianhuan Pharmaceutical's R&D expenses were 39.
12 million yuan, a year-on-year increase of 24.
3%
.
From 2018 to 2020, the company's R&D investment amounted to 38 million yuan, 47 million yuan and 44 million yuan, respectively, and the ratio of R&D investment to operating income during the same period was 3.
7%, 3.
6% and 3.
2%
.
According to public information, Bihuan Pharmaceutical is mainly engaged in the research and development, production and sales of chemical drugs.
The application scope of products covers several major series such as urinary system drugs, antihistamines, cardiovascular drugs, and steroid hormones, covering chemical raw materials, Various pharmaceutical dosage forms such as injections and solid preparations
.
Its main products are the innovative drug Aiprilide Tablets (Chuanliu), the new drug Ebastine Tablets (Sudi), Felodipine Tablets (Bicyclidine), and Felodipine Sustained-Release Capsules (Bicyclidine) , Simvastatin Tablets (Zhengzhi), Danazol Capsules and Suppositories, Metformin Gliclazide Tablets (Duhe), Lumbrokinase Capsules, Balofloxacin Tablets, Sertraline Hydrochloride Capsules (Bicyclopentine), etc.
More than ten
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The company's doxycycline hydrochloride tablets passed the consistency evaluation, and the company also became the first company to pass the evaluation of this variety
.
Up to now, Lianhuan Pharmaceutical has invested about 10.
5647 million yuan in research and development expenses for the consistency evaluation of the drug
.
Public information shows that doxycycline hydrochloride is a tetracycline antibiotic, a broad-spectrum bacteriostatic agent, mainly used for upper respiratory tract infections, tonsillitis, biliary tract infections, and lymphadenitis caused by sensitive gram-positive cocci and gram-negative bacilli.
, cellulitis, senile chronic bronchitis, etc.
, also used for typhus, scrub typhus, mycoplasma pneumonia and so on
.
In addition, it can also be used to treat cholera and to prevent falciparum malaria and leptospirosis infection
.
In China, the approved dosage forms of doxycycline hydrochloride include enteric-coated capsules, dispersible tablets, capsules, capsules, tablets, injections, etc.
, of which capsules occupy half of the country, followed by tablets and injections, accounting for 24.
06%, 22.
24%
.
Statistics from Minet.
com show that in 2019, the sales of full doxycycline dosage forms in the three major terminal public hospitals of cities, counties and townships in China were about 200 million yuan
.
There are many manufacturers of this variety.
According to incomplete data, doxycycline hydrochloride tablets alone have 61 companies in the domestic market, including Lianhuan Pharmaceutical, Dongfeng Pharmaceutical, Huanan Pharmaceutical, Daxin Pharmaceutical, Changzhou Pharmaceutical Factory, etc.
, a total of 77 production approvals
.
In terms of consistency evaluation, Lienhuan Pharmaceutical is the first company to pass the consistency evaluation of this variety
.
In addition, Teyi Pharmaceutical has also submitted a supplementary application for consistency evaluation
.
In recent years, policies such as centralized procurement and consistency evaluation have been successively introduced, which have a great impact on the market expansion of pharmaceutical products and profit growth
.
It is understood that in recent years, Lianhuan Pharmaceutical has adhered to the strategy of "innovating enterprises with science and technology and strengthening enterprises with science and technology", and has continuously strengthened related work such as the research and development of innovative drugs and the consistency evaluation of generic drugs.
Dr.
Ming has set up the company's doctoral workstation, continued to increase R&D investment and established an efficient R&D incentive mechanism.
Lihuan Pharmaceutical is making every effort to build a drug R&D highland, and the company has presented a good scientific and technological innovation atmosphere in which everyone pays attention to R&D and makes contributions
.
At the end of October 2021, the company received the "Approval Notice of Supplementary Drug Application" for ebastine tablets approved and issued by NMPA, and the company's ebastine tablets passed the consistency evaluation of generic drugs
.
Ebastine is a long-acting, highly selective histamine H1 receptor blocker indicated for allergic rhinitis with or without allergic conjunctivitis
.
In the first three quarters of 2021, Lianhuan Pharmaceutical's R&D expenses were 39.
12 million yuan, a year-on-year increase of 24.
3%
.
From 2018 to 2020, the company's R&D investment amounted to 38 million yuan, 47 million yuan and 44 million yuan, respectively, and the ratio of R&D investment to operating income during the same period was 3.
7%, 3.
6% and 3.
2%
.
According to public information, Bihuan Pharmaceutical is mainly engaged in the research and development, production and sales of chemical drugs.
The application scope of products covers several major series such as urinary system drugs, antihistamines, cardiovascular drugs, and steroid hormones, covering chemical raw materials, Various pharmaceutical dosage forms such as injections and solid preparations
.
Its main products are the innovative drug Aiprilide Tablets (Chuanliu), the new drug Ebastine Tablets (Sudi), Felodipine Tablets (Bicyclidine), and Felodipine Sustained-Release Capsules (Bicyclidine) , Simvastatin Tablets (Zhengzhi), Danazol Capsules and Suppositories, Metformin Gliclazide Tablets (Duhe), Lumbrokinase Capsules, Balofloxacin Tablets, Sertraline Hydrochloride Capsules (Bicyclopentine), etc.
More than ten
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
